Evidence map›Paper›PMID 36980269›Full record

ArticleCells2023

Zoledronic Acid Blocks Overactive Kir6.1/SUR2-Dependent K

Rosa Scala, Fatima Maqoud, Conor McClenaghan, Theresa M Harter, Maria Grazia Perrone, Antonio Scilimati, Colin G Nichols, Domenico Tricarico

Open access · goldFull text read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. CaInternational journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Rosa ScalaSections of Pharmacology, Medicinal Chemistry, Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.
Fatima MaqoudSections of Pharmacology, Medicinal Chemistry, Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.
Conor McClenaghanCenter for the Investigation of Membrane Excitability Diseases, Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110-1010, USA.
Theresa M HarterCenter for the Investigation of Membrane Excitability Diseases, Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110-1010, USA.
Maria Grazia PerroneSections of Pharmacology, Medicinal Chemistry, Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.ORCID 0000-0003-4195-5228
Antonio ScilimatiSections of Pharmacology, Medicinal Chemistry, Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.ORCID 0000-0003-2740-6425
Colin G NicholsCenter for the Investigation of Membrane Excitability Diseases, Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110-1010, USA.
Domenico TricaricoSections of Pharmacology, Medicinal Chemistry, Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.
University of Bari Aldo Moro · ITWashington University in St. Louis · US

Funding

Role of vascular KATP channels in Alzheimer’s neurodegeneration and dementiaR35HL140024 · NHLBI · WASHINGTON UNIVERSITY · PI NICHOLS, COLIN G · 2018 to 2023
$5.9M
Electrical excitability in vascular smooth muscle: from rare disease to new paradigmsR00HL150277 · NHLBI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI MCCLENAGHAN, CONOR · 2022 to 2024
$747k
Electrical excitability in vascular smooth muscle: from rare disease to new paradigmsK99HL150277 · NHLBI · WASHINGTON UNIVERSITY · PI MCCLENAGHAN, CONOR · 2020 to 2021
$200k
NHLBI NIH HHS K99 HL150277NHLBI NIH HHS R00 HL150277NHLBI NIH HHS R35 HL140024
6 · The paper itself

Abstract

Cantú syndrome (CS) is caused by the gain of function mutations in the

Indexed as

Muscle, SkeletalZoledronic AcidAdenosine TriphosphateAnimalsCardiomegalyDisease Models, AnimalGlyburideHypertrichosisKATP ChannelsMiceOsteoblastsOsteochondrodysplasiasSulfonylurea ReceptorsAbcc9 protein, mouseAdenosine TriphosphateGlyburideKATP ChannelsSulfonylurea ReceptorsuK-ATP-1 potassium channelZoledronic Acidanti-cancer drugATP-sensitive potassium channelCantú syndromeglibenclamidepatch clamprare diseaseskeletal musclezoledronic acid

Identifiers

PMID36980269
PMCPMC10047381
OpenAlexW4327951310

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read16
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.